In this study we analysed the incidence and clinical impact of the persistence of host haemopoiesis (mixed chimaerism, MC) after allogeneic BMT in 35 consecutive patients with haematologic malignancies using a total CD4
malignant clone by the conditioning regimen followed by the infusion of healthy donor marrow cells which re-establish normal haematologic and immune functions. However, the differences in post-transplant relapses between allogeneic and autologous or syngeneic BMT, 2, 3 and especially between in vitro T cell-depleted and unmanipulated allogeneic BMT, [3] [4] [5] indicate that allogeneic donor T cells play a pivotal role in the eradication of malignant cells, the socalled graft-versus-leukaemia (GVL) effect, and may be crucial for the development of complete donor haematopoiesis. Furthermore, graft failure and development of mixed chimaerism (MC, the coexistence of recipient and donor haematopoiesis) are more common after T cell-depleted BMT when compared with conventional transplants. [6] [7] [8] The true incidence and significance of the detection of MC post-BMT remain unclear. [6] [7] [8] [9] [10] However, with the use of increasingly sensitive molecular techniques for the detection of residual recipient cells, MC is frequently observed post-allogeneic BMT, [6] [7] [8] [9] [10] [11] [12] [13] although more important than simple documentation of the incidence of MC is an assessment of its relevance in relation to clinical outcome, particularly any correlation with relapse.
In order to provide the T cell-depleted marrow graft with a donor T cell potency that enables engraftment and the GVL effect but does not cause severe graft-versus-host disease (GVHD), in 1994 we initiated an approach of partial T cell depletion. 14 In this study, we investigated the incidence and the clinical impact of appearance and persistence of recipient haematopoiesis in serial samples taken from a group of 35 patients who had received BMT with adjusted number of CD8 ϩ cells in a CD4 ϩ cell-depleted graft. To determine the kinetics of growth of both donor and recipient cells during this period of 'cohabitation', we followed the percentage of host cells in all patients with MC after BMT.
We wished to answer three main questions. First, is the incidence of MC following this partial T cell depleted BMT similar to that observed after complete T cell depletion? Second, could the infusion of low doses of CD8 ϩ T lymphocytes ensure stable donor haematopoiesis and is it necessary for continued remission? Finally, could the detection of MC reliably predict relapse in this group of patients?
Patients and methods

Patients
During the study period, from March 1994 to June 1997, 35 consecutive patients with haematologic malignancies received partial T cell-depleted allogeneic BMT. Four patients died of procedure-related toxicity or early relapse within the first month post-BMT. A sample prior to BMT was not available in one case who was not evaluated for chimaerism. Thus, 30 patients were studied to determine whether post-transplant cells were of donor origin (complete donor chimaerism, DC) or also contained host cells (mixed chimaerism, MC). Eleven of 35 patients were transplanted for chronic phase CML; their clinical characteristics are outlined in Table 1 and the 24 remaining patients are summarised in Table 2 . Clinical results of the first 30 patients included here, in terms of GVHD incidence, engraftment and relapse rate, have been previously described. 14 In vitro partial T cell depletion of the marrow was performed by an immunomagnetic method as described in the clinical trial. 14 Two patients (UPN 235 and UPN 251) received donor leucocyte infusions (DLI) for relapsed CML, 6 and 35 months post-T cell-depleted BMT, respectively.
Isolation of genomic DNA
High molecular weight DNA was extracted from donor and recipient peripheral blood mononuclear cells before transplant, using a salting out procedure. 15 After BMT, DNA was extracted from patient peripheral blood at different intervals in order to determine the chimaerism status. When a recipient sample was not available prior to BMT, constitutional DNA isolated from hair roots was used according to Gill et al. 16 
PCR analysis of chimaerism
For PCR amplification, we used specific primers designed to flank the repeat units of the following human minisatellite regions (VNTR-PCR): D1S80, 33.6, 33.1, 33.4, YNZ- Table 1 Characteristics of patients who received T cell-depleted BMT for CML CML-CP = chronic myeloid leukaemia in chronic phase; TBI = total body irradiation; CY = cyclophosphamide; BU = busulphan; CsA = cyclosporin; MTX = methotrexate; MC = mixed chimaerism; DC = donor chimaerism; NE = not evaluable DFS = disease-free survival; R = relapse; * = death.
UPN
22, APO-B, g3, DXS52 and HVR-3. The sequence of the primers and conditions for each reaction have been described elsewhere. [17] [18] [19] [20] We define a VNTR locus as being informative if analysis of recipient and donor samples prior to BMT showed a unique band for the recipient and another unique band for the donor, or when they showed a unique band only for the recipient.
Patients who exhibited complete donor haematopoiesis with all markers tested at all times were defined as donor or complete chimaeras (DC). Patients who exhibited mixed populations of donor and host cells on more than one occasion with at least two different markers, after day 45 or when the recipient was transfusion-independent, were considered as mixed chimaeras (MC). The VNTR-PCR assay allows the detection of a minor cell population at the 0.5-1.5% level.
Quantitative VNTR-PCR
In order to evaluate the possible dynamics of chimaerism after BMT we established a quantitative PCR approach. Briefly, standardised mixed chimaeric samples were generated by mixing pretransplant recipient and donor DNA in a range of percentages for each individual case. PCR analysis for the informative locus was carried out on sequential patient samples using the informative primer pair. PCR products were separated by agarose gel electrophoresis. After staining with ethidium bromide, signals were analysed densitometrically and results were taken on the basis of individual standard curves. Post-BMT DNA samples were investigated in sequences and the signal intensities were compared to the standard curves.
RNA isolation
Total RNA was isolated from the patients' peripheral blood cells, fractionated on a Ficoll gradient, by acid guanidinium thiocyanate-phenol-chloroform extraction as described by Chomczynski and Sacchi. 21 For each preparation of RNA obtained from CML cells, a positive (cell line K506) and negative control (cell from healthy BMT donor) were Table 2 Characteristics of patients who received T cell-depleted BMT for non-CML ALL = acute lymphoblastic leukaemia; AML = acute myeloblastic leukaemia; MM = multiple myeloma; TBI = total body irradiation; CY = cyclophosphamide; BU = busulphan; MFL = melphalan; CsA = cyclosporin; MTX = methotrexate; MC = mixed chimaerism; DC = donor chimaerism; AR = autologous reconstitution; NE = not evaluable; NT = not tested; DFS = disease-free survival; R = relapse; VOD = veno-occlusive disease; GF = graft failure; IN = interstitial pneumonitis; * = death.
UPN
included. Each sample was divided into at least two aliquots and extracted separately on two different occasions.
In vitro amplification of BCR-ABL transcripts
Reverse transcription (RT) was performed on 1 g of total RNA, after heating at 70°C for 5 min, with random hexamers as reaction primers. The reaction was carried out at 42°C for 45 min in the presence of 12 units of AMV reverse transcriptase. Five microliters of RT products were used for two rounds of PCR amplification of the BCR-ABL transcripts using the protocol previously described by Saglio et al. 22 The second round PCR product was migrated in 1.5% agarose gel containing 1 g/ml ethidium bromide and photographed.
BCR-ABL negative cells were included in all RNA extraction procedures as negative controls in order to assess cross-contamination between RNA samples. A blank control that included all reagents except RNA was added at the cDNA stage to control for contamination with the PCR product. Precautions were taken in order to assure high PCR quality as recommended by Kwok and Higuchi. 23 Using this approach, we could detect a single BCR-ABL positive cell in 10 5 normal cells.
Cytogenetic analysis
For cytogenetic analyses, cells from bone marrow and/or peripheral blood were cultured in McCoy's medium supplemented with 20% fetal calf serum and antibiotics for 48 h. Chromosome preparations were stained with 5% Giemsa solution according to standard procedures. A minimum of 25 metaphases was analysed per sample. This allows the detection of a minor clone at the 5% level.
Statistical analysis
Frequencies of variables were compared by 2 statistics from contingency tables. Life tables for disease-free survival (DFS) were constructed by the method of KaplanMeier (1985), with differences compared by the log-rank test.
Results
Chimaerism and BCR-ABL mRNA assessment results
The chimaerism status was assessed prospectively in 30 of the 35 patients, from 1 to 51 months post-BMT. A median of eight analyses (range: 1-20) was performed for each patient post-BMT (Figures 1 and 2) . The percentage of patients with MC was 40% (12/30) and 18 patients had exclusively donor-derived blood cells.
Chimaerism in patients after BMT for CML: All 11 patients transplanted for CML had complete engraftment with a donor profile early post-BMT, but one patient developed late graft failure 5 months post-unrelated BMT (UPN 274). Of 11 patients, seven patients (63.6%) had MC, 
BCR-ABL mRNA assessment results:
Eleven patients with CML and two patients with Phϩ ALL were assessed for minimal residual disease (MRD) using RT-PCR for BCR-ABL mRNA. Follow-up ranged from 1 to 38 months post-BMT, and patients were assessed a median of seven times (range: 1-15) (Figures 1 and 2) .
Early BCR-ABL positivity post-BMT was seen in 7/11 patients with CML. Two patients (UPN 235 and 274) had continuous positive PCR results and subsequently developed recurrence of CML. In one patient (UPN 292) follow-up samples at 5 months were PCR negative. While in four patients (UPNs 245, 251, 304 and 267) PCR positivity reappeared prior to relapse. The remaining four patients with CML and patients with Phϩ ALL showed no evidence of BCR-ABL mRNA at any time post-BMT during the study.
Chimaerism in patients after BMT for non-CML:
The DC status was detected initially in 16 cases within the group of 19 patients with malignant diseases other than CML, and two patients (UPN 255 with AML and UPN 261 with ALL) who developed transient MC before day ϩ60, converted subsequently to DC and remain in complete remission. Five patients developed MC during the observation period (26%). Patients who initially exhibited MC (UPN 232 with AML and UPN 303 with MDS) and subsequently showed increasing amounts of autologous DNA, eventually relapsed. However, two patients (UPN 220 with ALL and 252 with AML) showed a stable level of mixed chimaerism in complete continuous remission for 4 and 3 years, respectively (Figure 3a) . In addition, one of 19 patients (UPN 310 with unrelated-BMT for ALL) recovered autologous marrow, but neither engraftment delay nor relapse were documented during the study period, despite the persistence of Ͼ95% of recipient cells. 
MC, MRD and relapse
Sixteen of 35 T cell-depleted BMT patients remain in clinical and cytogenetic remission with a median follow-up of 27 months (range: 3.1-51) post-BMT. Sixteen of 30 patients available for analysis by VNTR-PCR, who were donor chimaeras in serial samples during the study period, all remain in remission (Tables 1 and 2) . Two patients who initially showed MC but converted to full DC also remain in remission 18 and 36 months post-BMT. However, eight of 12 patients who had evidence of persistent detection of recipient cells, showed subsequent relapse, with an unfavourable probability of remaining disease-free when compared with patients who exhibited DC (24.73 Ϯ 13.62% vs 100%, P = 0.0055) (Figure 4a and b) .
Interestingly, patients with increasing amounts of autologous DNA, eventually relapsed, whereas patients who achieved low-stable MC on follow-up (UPNs 220 and 252), maintained complete remission. In addition we have seen two unusual cases with full autologous reconstitution, without evidence of molecular or clinical relapse.
More important, we found that 86% of CML who were MC following T cell-depleted BMT relapsed, compared to only 40% of non-CML and MC. Moreover, the study of MRD showed that BCR-ABL mRNA positivity was present prior to the establishment of MC profile in all patients transplanted for CML who developed recurrence of disease.
GVHD and chimaerism
Acute GVHD grade II appeared in four of 18 (22%) patients with DC and in one patient of 12 with mixed haematopoiesis (8%) (not significant). Acute GVHD grade III-IV was not observed in this study. Chronic GVHD occurred in five patients with DC (41%) and in one patient with MC (10%, not significant). Additionally, MC was detectable in eight of 18 patients (45%) treated with shortcourse methotrexate and CsA, and in four of 12 patients (33%) who received CsA alone for additional GVHD prophylaxis (Table 3) .
Discussion
This study analysed the impact of a model of partial T cell depletion in post-transplant haematologic chimaerism pat- ϩ T lymphocytes in donor bone marrow can ensure donor engraftment. At the end of the study period our global incidence of MC was about 40%, whereas an unexpected absence of MC was found by Gallardo et al 24 in their series using a similar method of T cell depletion.
Generally, a higher incidence of persistent recipient haematopoietic cells is found following T cell-depleted BMT (50% to 100%), [6] [7] [8] 10, 12, 13 suggesting that T cells may play a role in maintenance of complete donor haematopoiesis. Our MC rate was not substantially lower than those reported after complete T cell depletion and it was found to be greater than that seen after unmanipulated grafts, especially in CML transplanted in chronic phase 26, 27 (approximately 20%) as compared to 64% in our patients.
Documentation of the incidence of MC provides only limited information about its clinical impact. More useful data can be obtained from correlation of serial and quantitative analyses with clinical outcome. Different interpretations of the significance of MC after BMT have been reported. It is likely that this will vary according not only to the number and type of alloreactive cells infused, but also to the immunosuppressive drug therapy used to prevent GVHD and to the underlying disease. In this sense, Elmaagacli et al 28 found that by modifying GVHD prophylaxis, the incidence of mixed chimaeras changes. By contrast, we and others 12, 29 using T cell depletion did not observe a significant correlation either between the incidence of GVHD or different schedules of GVHD prophylaxis, due probably to the low frequency of GVHD.
Likewise, studies on the association between the occurrence of MC and the increased risk of relapse have been a matter of controversy. In our study, all 18 patients who had evidence of stable donor chimaerism (ie complete donor or transient MC) in serial samples remain in remission. By contrast, patients who showed MC carried a significantly enhanced risk of developing relapse (P = 0.005), and it is of interest that patients with increasing amounts of autologous patterns subsequently relapsed, while patients who achieved a stable low level of host haematopoietic cells remained in continuous remission. These results are also consistent with those that found no relapse in patients without MC post-BMT. 8, 13, [26] [27] [28] [29] [30] [31] Interestingly, we found no evidence of a clear relationship between MC and relapse after BMT for non-CML disease (only two of five patients with MC have relapsed) in marked contrast to our experience in CML. Roux et al 32 speculated that the clinical impact of MC depends on the underlying disease. Our findings support this hypothesis and imply that the development of tolerance as indicated by MC is not necessarily associated with relapse after T depleted BMT for non-CML diseases. Thus, the persistence of MC in these patients may demonstrate the persistence of residual healthy host-type cells, which may have a growth advantage over malignant cells, and also of surveillance by allogeneic immune effector cells.
Of further interest, a clear correlation could be made between the evolution of progressive MC and clinical outcome in CML in this study. It is in accordance with the very similar relapse rate seen after total T cell depletion. 8, 29, 30 It makes biologic sense and it is compatible with the concept that the GVL effect against CML is mainly exerted by donor CD4 ϩ lymphocytes. 33 Elimination of this cellular subset may be responsible for the incompetence of the graft to eradicate surviving host haematopoiesis.
In addition, MRD was present prior to detection of a MC profile and subsequent relapse. Thus our molecular data of increasing autologous DNA, after BCR-ABL mRNA positivity, seem to be a reflection of the decreasing amounts of donor GVL effector cells, which allows a gradual and progressive increase in the tumor cell burden in those patients destined to relapse. Moreover, the quantification of recipient cell levels by measuring the relative intensities of the VNTR bands and analysis of consecutive samples, allows the relative decrease or increase of host cell levels to be determined without recourse to technically difficult quantitative BCL-ABL PCR tests, 34 providing useful information on the proliferative activity of the residual leukaemic clone in non-CML diseases without specific markers.
Taken together, the results suggest that the infusion of low doses of CD8 ϩ lymphocytes may support early complete donor haematopoiesis post-transplant. However, there is no evidence that the same cells prevent the regrowth of recipient cells, given that CD4 ϩ T cells may be needed to prevent the appearance of MC, which adversely affect the prognosis of BMT patients, especially in CML.
One interesting implication of our study is that MC appears to be an active phenomenon that results from the interactions of various subsets of donor and recipient cells. Moreover, when MC develops it will be of interest to better define the implications of each population and their contribution to the GVL effect.
